SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

Medication

Tirzepatide: Mounjaro and Zepbound Explained

Tirzepatide is a once-weekly injectable medication sold as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management and obstructive sleep apnea). Unlike semaglutide, it activates two gut-hormone receptors — GLP-1 and GIP — simultaneously. In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% body-weight loss versus 13.7% for semaglutide over 72 weeks.

Written by Gale Editorial · grounded in the cited clinical sources below · Updated 2026-06-15. How we write.

Drug facts

Generic name:
tirzepatide
Class:
Dual GIP and GLP-1 receptor agonist (incretin mimetic)
Brand names:
Mounjaro, Zepbound
How it's taken:
Subcutaneous injection, once weekly

Talk to a clinician

Gale can match you with a clinician licensed in your state — the honest cost shown before you book.

Find care →

What tirzepatide is — and the two brand names

Tirzepatide is the active molecule behind two brand-name drugs made by Eli Lilly:

  • Mounjaro — FDA-approved in May 2022 for blood-sugar control in adults with type 2 diabetes 1
  • Zepbound — FDA-approved in November 2023 for chronic weight management, and in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity 1

Both are the same molecule at the same doses. The separate brand names exist because FDA approval is indication-specific: Mounjaro is the diabetes label; Zepbound is the weight-management and sleep-apnea label. This distinction matters for insurance — a plan that covers Mounjaro for a diabetes diagnosis may not cover Zepbound for weight loss, and vice versa.

Tirzepatide is not an oral pill. It is injected subcutaneously (under the skin of the abdomen, thigh, or upper arm) once per week, with or without meals 2.

How tirzepatide works — the dual receptor mechanism

Most GLP-1 drugs (semaglutide, liraglutide) activate a single gut-hormone receptor. Tirzepatide activates two: the GLP-1 receptor and the GIP receptor. This is why it is called a dual GIP/GLP-1 receptor agonist — the first approved drug of its class 3.

GLP-1 (glucagon-like peptide-1) is released by the intestine after eating. Activating its receptor: - Signals the pancreas to release insulin when blood glucose is elevated - Suppresses glucagon (the hormone that raises blood sugar) - Slows gastric emptying, so food moves through the stomach more slowly - Acts on appetite centers in the brain to reduce hunger

GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone. Its receptor activation amplifies insulin secretion further, enhances fat-cell metabolism, and may contribute to additional appetite suppression through distinct neural pathways.

Research in *JCI Insight* showed tirzepatide is an "imbalanced" agonist: it binds the GIP receptor with affinity equivalent to native GIP but the GLP-1 receptor with approximately five-fold weaker affinity, producing a biased signaling pattern that favors cAMP generation and may amplify insulin secretion 3. The net clinical result is lower blood sugar, slowed gastric emptying, and — at current doses — larger average weight loss than any previously approved drug in this class.

What the clinical trials show

SURMOUNT-1 (tirzepatide vs. placebo, 2022): In 2,539 adults with obesity or overweight (no diabetes), tirzepatide produced weight losses of −16.0% (5 mg), −21.4% (10 mg), and −22.5% (15 mg) versus −2.4% for placebo at 72 weeks. About 96% of participants on the two highest doses achieved at least 5% weight loss 4.

SURMOUNT-5 (tirzepatide vs. semaglutide, head-to-head, 2025): The first direct randomized comparison between tirzepatide and semaglutide, published in *NEJM* in 2025. In 751 adults with obesity (no diabetes), randomized to maximum tolerated doses of either drug for 72 weeks 1:

| Outcome | Tirzepatide | Semaglutide | |---|---|---| | Mean body-weight loss | −20.2% | −13.7% | | Absolute weight loss | −22.8 kg | −15.0 kg | | Waist circumference reduction | −18.4 cm | −13.0 cm | | Achieved ≥25% weight loss | 31.6% | 16.1% | | Discontinued for GI events | 2.7% | 5.6% |

The difference was statistically significant (p<0.001). Tirzepatide produced approximately 47% greater relative weight loss.

Real-world data (2026): A 6-month retrospective cohort study (n=2,396, US clinical practice) found tirzepatide achieved 11.15% mean weight loss versus 8.83% for semaglutide, with tirzepatide superior on all clinical thresholds (≥5% through ≥20%) 5.

FDA-approved indications and who qualifies

Tirzepatide (Zepbound) is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. It is used alongside a reduced-calorie diet and increased physical activity 2.

In December 2024, Zepbound became the first FDA-approved medication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial showing significant reductions in apnea-hypopnea events versus placebo 1.

For type 2 diabetes, Mounjaro is the labeled form. In the SURPASS clinical program, tirzepatide lowered HbA1c by up to −2.34 percentage points at 15 mg.

Tirzepatide is not approved for type 1 diabetes, for pediatric use (adult indication only), or for patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

Side effects

The most common side effects are gastrointestinal, most pronounced during dose escalation and typically lessening over time 2.

Common: nausea, diarrhea, vomiting, constipation, abdominal discomfort, decreased appetite, fatigue, injection-site reactions, hair loss (with weight-loss use).

Serious — contact a clinician promptly: - Pancreatitis: Severe abdominal pain radiating to the back. Confirmed acute pancreatitis occurred in 0.2% of tirzepatide-treated patients in pooled Zepbound trials (vs. 0.2% placebo) 2. - Gallbladder disease: Gallstones risk rises with rapid weight loss. - Acute kidney injury: Usually from dehydration during GI illness. - Hypoglycemia: A risk primarily when combined with a sulfonylurea or insulin. - Serious allergic reactions: Including anaphylaxis — rare but reported.

FDA Boxed Warning — Thyroid C-cell tumors: In rodent studies, tirzepatide caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma. Whether this applies to humans is unknown. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome 2.

Tirzepatide is not recommended during pregnancy. Hormonal contraceptives may be less effective for up to four weeks after starting or increasing the dose 2.

Dosing overview

Tirzepatide is started at the lowest dose and titrated upward every four weeks to minimize GI side effects 2:

  • Starting dose: 2.5 mg once weekly (initiation only; not a maintenance dose)
  • Titration: increase by 2.5 mg every 4 weeks
  • Doses available: 2.5, 5, 7.5, 10, 12.5, 15 mg
  • Maximum dose: 15 mg once weekly

In both SURMOUNT-1 and SURMOUNT-5, maintenance doses were 5–15 mg. SURMOUNT-5 used maximum tolerated dose, so not all participants reached 15 mg — individual tolerance sets the ceiling. A missed dose can be taken if the next injection is more than four days away; if fewer than four days remain, the missed dose is skipped 2.

Cost and access

Cost remains a significant access barrier.

  • List price (pen injector): approximately $1,086/month for Zepbound as of 2025
  • LillyDirect cash vials: $299/month (2.5 mg) to $449/month (10–15 mg), available without insurance through the manufacturer's direct program
  • Savings card: for commercially insured patients (not Medicare/Medicaid), out-of-pocket cost can fall to approximately $25/month
  • Insurance: many plans cover Mounjaro for a diabetes diagnosis but deny Zepbound for weight management; prior authorization usually requires documented BMI and sometimes evidence of a supervised diet program; Medicaid coverage varies by state
  • Medicare Part D: coverage of Zepbound for weight loss remains limited as of mid-2026; the OSA indication may differ by plan
  • Patient assistance: the Lilly Cares Foundation offers support for patients below certain income thresholds (lilly.com)

Common questions

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide at the same doses, made by the same manufacturer (Eli Lilly). Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea. The distinction is the approved indication on the label, which affects insurance coverage.

Is tirzepatide better than semaglutide for weight loss?

In the SURMOUNT-5 head-to-head trial (2025, NEJM), tirzepatide produced 20.2% body-weight loss versus 13.7% for semaglutide over 72 weeks — approximately 47% greater relative weight loss. However, semaglutide (Wegovy) has an FDA-approved cardiovascular outcomes indication that tirzepatide does not currently have, and individual responses vary.

How long does it take for tirzepatide to work?

Meaningful weight loss typically becomes apparent over the first 4–12 weeks on a maintenance dose. The full weight-loss effect builds over many months; the SURMOUNT-1 trial measured results at 72 weeks. Blood sugar improvements in diabetes patients can occur sooner. MedlinePlus notes that full benefit may take 4 or more weeks to become apparent.

What are the most common side effects of tirzepatide?

Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are the most common — all gastrointestinal. These are most pronounced during dose escalation and improve for most people over time. In the SURMOUNT-5 trial, GI-related discontinuations occurred in 2.7% of tirzepatide participants, compared to 5.6% for semaglutide.

Who should not take tirzepatide?

Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not recommended during pregnancy. It is not approved for type 1 diabetes. Patients with a history of pancreatitis, gallbladder disease, or serious hypersensitivity to GLP-1 drugs should discuss risks carefully with their clinician.

How much does Zepbound cost without insurance?

The list price for Zepbound pens is approximately $1,086 per month. Eli Lilly's LillyDirect cash program offers single-dose vials starting at approximately $299/month for the lowest doses and up to $449/month for 10–15 mg doses. A manufacturer savings card reduces out-of-pocket costs to roughly $25/month for eligible commercially insured patients.

Related conditions

Condition/Glp 1 Muscle Loss

Related medications

Drug/Mounjaro · Drug/Zepbound · Drug/Semaglutide Vs Tirzepatide · Drug/Semaglutide · Drug/Wegovy · Drug/Ozempic · Drug/Glp 1 Agonists

Specialties

Specialty/Primary Care

Talk to a clinician

Say what's going on in your own words. Gale finds a clinician licensed in your state and shows the real cost before you book.

Find care →

When to seek care

  • —Severe abdominal pain that radiates to the back — possible pancreatitis; stop the medication and seek emergency care
  • —Signs of a serious allergic reaction: hives, swelling of the face or throat, difficulty breathing
  • —Yellowing of skin or eyes, severe right upper abdominal pain — possible gallbladder disease
  • —Decreased urination, unusual swelling, dark urine — possible kidney injury, often from dehydration during GI illness
  • —A lump or swelling in the neck, hoarseness, or difficulty swallowing — possible thyroid abnormality; contact a clinician promptly
  • —Rapid or irregular heartbeat that is new or worsening
  • —Vision changes (especially in patients with type 2 diabetes — report to an eye doctor)
  • —Symptoms of low blood sugar if also taking a sulfonylurea or insulin: shakiness, sweating, confusion

Call 911 or go to the nearest emergency room for severe abdominal pain, difficulty breathing, or signs of anaphylaxis.

General health information, not medical advice. Synthetic demonstration content.

References

  1. 1.Aronne LJ, Bade Horn D, le Roux CW et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. doi:10.1056/NEJMoa2416394 ✓SURMOUNT-5 head-to-head RCT: tirzepatide −20.2% vs semaglutide −13.7% body weight at 72 weeks; waist circumference −18.4 cm vs −13.0 cm; GI discontinuation 2.7% vs 5.6% (p<0.001). Also cited for Zepbound November 2023 weight-management approval and December 2024 OSA approval.
  2. 2.U.S. Food and Drug Administration / Eli Lilly and Company (2023). Zepbound (tirzepatide) Prescribing Information. FDA / MedlinePlus (NLM). link ✓Approved indications, dosing schedule (2.5 mg start, 2.5 mg increments every 4 weeks, max 15 mg weekly), contraindications (MTC/MEN 2), boxed warning (thyroid C-cell tumors in rodents), adverse-reaction profile (nausea, diarrhea, vomiting, pancreatitis 0.2%), pregnancy and contraception cautions
  3. 3.Willard FS, Douros JD, Gabe MBN et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. doi:10.1172/jci.insight.140532 ✓Mechanism: tirzepatide binds GIPR with affinity equivalent to native GIP but binds GLP-1R with approximately 5-fold weaker affinity; biased GLP-1R signaling favors cAMP over beta-arrestin recruitment; explains dual-pathway mechanism and potential for enhanced insulin secretion
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. doi:10.1056/NEJMoa2206038 ✓SURMOUNT-1 Phase 3 RCT (n=2,539): tirzepatide 5/10/15 mg produced −16.0%/−21.4%/−22.5% body-weight loss vs −2.4% placebo over 72 weeks; 96% of 10 mg and 15 mg participants achieved ≥5% weight loss; primary pivotal trial supporting Zepbound FDA approval
  5. 5.le Roux CW, Done N, Brnabic AJM et al. (2026). Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. Journal of Endocrinological Investigation. doi:10.1007/s40618-025-02792-1 ✓Real-world cohort (n=2,396 US patients without diabetes, 6 months): tirzepatide −11.15% vs semaglutide −8.83% mean weight loss; tirzepatide superior on all clinical weight-loss thresholds (≥5%, ≥10%, ≥15%, ≥20%) and blood pressure reduction

https://www.gale.care/drugs/tirzepatide · 5 sources. General health information, not medical advice — synthetic demonstration content.